NCT00492869已完成1 期
A 12-month Open-label, Randomized, Multicenter, Sequential Cohort, Dose Finding Study to Evaluate the Efficacy, Safety and Tolerability of Oral AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Corticosteroids in de Novo Adult Renal Transplant Recipients
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 124
- 试验地点
- 54
- 主要终点
- Efficacy will be defined using a composite efficacy failure end point (treated biopsy proven acute rejection (BPAR), graft loss, death or loss to follow-up) between treatment and control arms
研究概览
简要总结
Efficacy and safety of AEB071 in combination with mycophenolate acid sodium, basiliximab and steroids in preventing acute rejection after kidney transplantation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Efficacy will be defined using a composite efficacy failure end point (treated biopsy proven acute rejection (BPAR), graft loss, death or loss to follow-up) between treatment and control arms
次要结局
- Renal function assessed by calculated and measured glomerular filtration rate (GFR). Incidence of Chronic Allograft Nephropathy using biopsies
研究者
研究点 (54)
Loading locations...
相似试验
已完成
2 期
Safety, Tolerability, and Efficacy of AEB071 in the Treatment of UveitisPosterior UveitisPanuveitisUveitisNCT00615693Novartis13
已完成
2 期
Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant RecipientsKidney TransplantationNCT00504543Novartis Pharmaceuticals311
已完成
2 期
Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative ColitisUlcerative ColitisNCT00572585Novartis Pharmaceuticals60
终止
1 期
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal MelanomaUveal MelanomaNCT01801358Array Biopharma, now a wholly owned subsidiary of Pfizer38
招募中
1 期
Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular CarcinomaSafety IssuesEfficacyMTDNCT06141109Xi'an Xintong Pharmaceutical Research Co.,Ltd.39